The Exploratory Study on the Nicotinamide Mononucleotide (Vital NAD ) to Promote the Rejuvenation of the Peripheral Blood Immune Cells of Adults.

Shanghai Cell Therapy Group

Status and phase

Not yet enrolling

Early Phase 1

Conditions

Enhance Immune Function

Treatments

Drug: NMN

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT05984550

CH2301-A-02

Details and patient eligibility

About

The purpose of this study is to investigate the changes in adult peripheral blood immune cell subpopulations, subpopulations, and cell functional status before and after intervention with Nicotinamide Mononucleotide (Vital NAD ) as NAD+ supplement for a certain period of time。To Explore and validate the biological functions of Nicotinamide Mononucleotide (Vital NAD ) of rejuvenation of the Peripheral blood immune cells of Adults.

Full description

This study focuses on the effects of Nicotinamide mononucleotide (Vital NAD) as NAD+ supplement on the subtypes and biological functions of immune cells of Adults, especially the types and subsets of immune cells, immune cell differentiation, and immune cell status indicators. Therefore, this study plans to enroll approximately 20 adult subjects in a daily dose of 600mg/day and receive 30 days of Nicotinamide Mononucleotide (Vital NAD) intervention. The study will evaluate the improvement effect of NMN intervention on human immune cell research indicators before and after intervention. The study will also study the impact of NMN on Hematology and blood biochemical indicators, and evaluate the changes of human Hematology biological age after NMN intervention.

Enrollment

10 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male/females of 18 to 80 years of age.
Able to provide written Informed Consent.
BMI 25.0-44.9 kg/m².
Able to follow verbal and written study directions.
Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.
Able to maintain consistent diet and lifestyle habits according to the study.

Exclusion criteria

1. Diabetes.
2.Premenopausal or menopause <1 year.

3.Persons who have received hormone replacement therapy within the past 6 months.

4.Persons who take vitamin B supplementation and are not willing to discontinue supplementation for 3 weeks before and during the entire study period.

5.Unstable weight (>3% change during the last 2 months before entering the study).

6.Significant organ system dysfunction or disease.

7.Present cancer or history of cancer that has been in remission for <5 years.

8.Polycystic ovary syndrome.

9.Major psychiatric illness.

10.Use of medications known to affect study outcome measures (e.g., steroid) or increase the risk of study procedures (e.g., anticoagulants) that cannot be temporarily discontinued for the study.

11.Metal implants.

12.Persons who consume >14 units of alcohol per week.

13.Unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.